Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $13.63 USD
Change Today -0.09 / -0.66%
Volume 7.4K
OXFD On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 2:48 PM 04/21/15 All times are local (Market data is delayed by at least 15 minutes).

oxford immunotec global plc (OXFD) Snapshot

Open
$13.80
Previous Close
$13.72
Day High
$14.20
Day Low
$13.63
52 Week High
05/12/14 - $20.00
52 Week Low
12/12/14 - $10.01
Market Cap
306.8M
Average Volume 10 Days
21.9K
EPS TTM
$-1.28
Shares Outstanding
22.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OXFORD IMMUNOTEC GLOBAL PLC (OXFD)

Related News

No related news articles were found.

oxford immunotec global plc (OXFD) Related Businessweek News

No Related Businessweek News Found

oxford immunotec global plc (OXFD) Details

Oxford Immunotec Global PLC, a diagnostics company, develops and commercializes proprietary tests for the management of immune-regulated conditions in the United States, Europe, Japan, and China. The company develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immunologically controlled diseases. Its solution includes SPOT.TB test, a single-cell based method for identifying latent tuberculosis infection. The company was founded in 2002 and is headquartered in Abingdon, the United Kingdom.

240 Employees
Last Reported Date: 03/5/15
Founded in 2002

oxford immunotec global plc (OXFD) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $330.4K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $255.0K
Chief Commercial Officer
Total Annual Compensation: $276.8K
Compensation as of Fiscal Year 2013.

oxford immunotec global plc (OXFD) Key Developments

Oxford Immunotec Global PLC Announces Availability of the T-SPOT.CMV Test in the United States

Oxford Immunotec Global PLC announced the availability in the United States of a new test that measures the strength of a patient's cellular immune response to cytomegalovirus (CMV). This T-SPOT(R).CMV test is available as a Laboratory Developed Test from the Company's CLIA-certified and CAP accredited service laboratory. T cell immunity against CMV is a factor in controlling viral latency and susceptibility to CMV disease. CMV can affect individuals with weaknesses in their T cell response and it is therefore an important and common cause of morbidity and mortality in solid organ and hematopoietic stem cell transplant recipients. The T-SPOT.CMV test measures the strength of T cell responses to CMV specific antigens. The T-SPOT.CMV test has the potential to assist clinicians with monitoring anti-viral prophylaxis and evaluating patients at risk from CMV disease. The T-SPOT.CMV test leverages Oxford Immunotec's proprietary T-SPOT technology platform. The new test will be performed at Oxford Diagnostic Laboratories in Memphis, TN, where validation was performed. The test results will be available to customers within two days of receipt of a whole blood sample. The T-SPOT.CMV test builds on Oxford Immunotec's capabilities in T cell measurement technology, and is the first in a series of planned new products intended to help transplant patients and physicians manage immune regulated conditions. The T-SPOT.CMV test is pending approval in California, New York and Florida.

Oxford Immunotec Global PLC Appoints Stephen M. Gansler as Senior Vice President and Global Head of Human Resources

Oxford Immunotec Global PLC announced that Stephen M. Gansler has joined the company as Senior Vice President and Global Head of Human Resources. Most recently, Mr. Gansler was Senior Vice President, Human Resources, for Millennium Pharmaceuticals.

Oxford Immunotec Global PLC Announces Unaudited Consolidated Earnings Results for the Fourth Quarter Full Year Ended December 31, 2014; Provides Revenue Guidance for First Quarter and Full Year of 2015

Oxford Immunotec Global PLC announced unaudited consolidated earnings results for the fourth quarter full year ended December 31, 2014. For the quarter, the company reported total revenue of $12,118,000 compared to $10,225,000 a year ago. Loss from operations was $6,723,000 compared to $2,148,000 a year ago. Loss before income taxes was $6,617,000 compared to $3,271,000 a year ago. Net loss was $6,692,000 compared to $3,328,000 a year ago. Basic and diluted net loss per share attributable to ordinary shareholders was $0.39 compared to $0.38 a year ago. LBITDA was $6,166,000 compared to $2,961,000 a year ago. Adjusted LBITDA was $5,426,000 compared to $1,712,000 a year ago. For the full year, the company reported total revenue of $49,505,000 compared to $38,784,000 a year ago. Loss from operations was $21,861,000 compared to $7,351,000 a year ago. Loss before income taxes was $22,020,000 compared to $8,572,000 a year ago. Net loss was $22,174,000 compared to $8,664,000 a year ago. Basic and diluted net loss per share attributable to ordinary shareholders was $1.28 compared to $2.26 a year ago. LBITDA was $20,226,000 compared to $7,143,000 a year ago. Adjusted LBITDA was $17,664,000 compared to $6,008,000 a year ago. For the full year of 2015, the company expected revenue will be in the range of $60 million and $65 million, representing 21%-31% year-over-year growth. For the first quarter of 2015, the company expected revenue will be in the range of $13.2 million and $13.7 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OXFD:US $13.63 USD -0.09

OXFD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OXFD.
View Industry Companies
 

Industry Analysis

OXFD

Industry Average

Valuation OXFD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.8x
Price/Book 4.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OXFORD IMMUNOTEC GLOBAL PLC, please visit www.oxfordimmunotec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.